Author: LISA J. BAIN Date: February 8, 1993, pp.21 About five or 10 years ago, good scientific credentials were enough to land a job in industry, human resources experts say. But hiring managers report that times have changed. In today's high-technology companies, teamwork is the key to developing technological products and bringing them to market, they say. And effective teamwork requires the ability to communicate both vertically and horizontally through an organization. As a result, interp

Godwin Ananaba says it was a chance meeting with a friend that eventually led him to become a researcher in Larry J. Anderson's lab at the Center for Infectious Diseases in Atlanta (part of the Public Health Service's Centers for Disease Control, or CDC). The friend told Ananaba about the Washington, D.C.-based National Research Council's research associateship program, a program widely known to foreign students seeking postdoctoral fellowships but underutilized by, and even unknown to, many Am

Making the transition from clinical training to basic research can be difficult for a young scientist; it's almost like starting a new career. With no research track record, getting established and obtaining funding loom as monumental tasks. This was the prospect facing William Honer when he finished his psychiatry residency at Columbia University. Fortunately for Honer and others like him in the field of psychiatry, assistance was available. The Chicago-based National Alliance for Research on

Research stalls as a commercial agreement on the technology's future eludes Cytogen and the University of Pennsylvania Last year, two University of Pennsylvania biologists crossed the species barrier in a big way. Little did they know that their feat would lead to crossfire between their institution and the company that sponsored the work. Nor did they anticipate that continued scientific progress would be a casualty of this skirmish. Last July, Jean Richa and Cecilia Lo announced in Science (

Analysts say the Roche deal blunts the impact of a report in which the firm's top product fares poorly against its competition Genentech took it on the chin last month when a massive study by Italian scientists found that tPA, tissue plasminogen activator, was no more effective in treating heart attacks than streptokinase, a bacterial enzyme that costs one tenth as much. But the stock price of the South San Francisco, Calif., company, which manufactures the drug, hardly budged. Although tPA i

The chemical giant, looking for a better research climate, joins other German firms in the Western Hemisphere Eluding pressure from environmentalists and biotechnology regulators at home while looking for new markets to conquer abroad, the West German chemical giant BASF Corp. is establishing a foothold in the United States, with a $100 million research facility at the Massachusetts Biotechnology Park in Worcester. BASF's decision in 1988 to set up shop in the U.S. is the latest example of an